{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:02:59Z","timestamp":1767988979871,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2023YFS0111"],"award-info":[{"award-number":["2023YFS0111"]}]},{"name":"Project for Disciplines of Excellence, West China Hospital, Sichuan University","award":["ZYJC21043"],"award-info":[{"award-number":["ZYJC21043"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A combination of chemotherapy and immune checkpoint inhibitor therapy has been demonstrated to be effective as a first-line treatment of gastric or gastro-oesophageal junction (G\/GEJ) cancer. The conventional treatment strategy for patients with advanced\/metastatic human epidermal growth factor receptor 2-negative G\/GEJ cancer is recommended. However, the response rate and enhancements in survival are still significantly insufficient. The present study will investigate the efficacy and safety of incorporating a bevacizumab biosimilar IBI305 into chemotherapy and immunotherapy as a first-line treatment for advanced or metastatic G\/GEJ cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This single-arm, open-label, prospective phase Ib\/II clinical study will involve 57 participants. In phase Ib of the trial, patients with advanced or metastatic G\/GEJ cancer will receive capecitabine and oxaliplatin (CapeOX) together with sintilimab (200\u2009mg intravenously every 3 weeks) and IBI305 (7.5, 10 or 15\u2009mg\/kg intravenously every 3 weeks) in a 3+3 dose-escalation design to evaluate dose-limiting toxicities (DLTs) within 6 weeks of treatment initiation. In phase II, the patients will receive CapeOX combined with sintilimab and IBI305 at the recommended phase II dose. The primary objectives will be to assess DLTs (phase Ib) and the objective response rate (phase II). The secondary objectives will include progression-free survival, overall survival, disease control rate, duration of response, adverse effects, quality of life and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial protocol was approved by the Ethics Committee of West China Hospital and ClinicalTrials. The final results will be published in a peer-reviewed journal upon completion of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05640609\">NCT05640609<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-086005","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:40:24Z","timestamp":1767969624000},"page":"e086005","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib\/II trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05640609","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-2995","authenticated-orcid":false,"given":"Ruihong","family":"Dai","sequence":"first","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4972-6412","authenticated-orcid":false,"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gastric Cancer Center, Sichuan University, Chengdu, Sichuan Province, China"},{"name":"Department of Abdominal Oncology, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Gastric Cancer Center, Sichuan University, Chengdu, Sichuan Province, China"},{"name":"Department of Abdominal Oncology, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastric Cancer Center, Sichuan University, Chengdu, Sichuan Province, China"},{"name":"Department of Abdominal Oncology, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026010906401623000_16.1.e086005.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02170"},{"key":"2026010906401623000_16.1.e086005.2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(75)90482-9"},{"key":"2026010906401623000_16.1.e086005.3","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.21037\/jgo-22-818","article-title":"Current management of gastric adenocarcinoma: a narrative review","volume":"14","author":"Nevo","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"2026010906401623000_16.1.e086005.4","doi-asserted-by":"crossref","first-page":"152882","DOI":"10.1016\/j.prp.2020.152882","article-title":"The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer","volume":"216","author":"Xi","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2026010906401623000_16.1.e086005.5","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.014.10123"},{"key":"2026010906401623000_16.1.e086005.6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"The Lancet"},{"key":"2026010906401623000_16.1.e086005.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"2026010906401623000_16.1.e086005.8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026010906401623000_16.1.e086005.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00823-9"},{"key":"2026010906401623000_16.1.e086005.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-41177-2","article-title":"PD-L1 expression combined with microsatellite instability\/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer","volume":"9","author":"Morihiro","year":"2019","journal-title":"Sci Rep"},{"key":"2026010906401623000_16.1.e086005.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"2026010906401623000_16.1.e086005.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9824"},{"key":"2026010906401623000_16.1.e086005.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5322-0","article-title":"VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer","volume":"19","author":"Lian","year":"2019","journal-title":"BMC Cancer"},{"key":"2026010906401623000_16.1.e086005.14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12231","article-title":"Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia\/lymphoma mouse model","volume":"92","author":"Mori","year":"2014","journal-title":"Eur J Haematol"},{"key":"2026010906401623000_16.1.e086005.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"2026010906401623000_16.1.e086005.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30156-X"},{"key":"2026010906401623000_16.1.e086005.17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hepr.13693","article-title":"Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria","volume":"51","author":"Sho","year":"2021","journal-title":"Hepatol Res"},{"key":"2026010906401623000_16.1.e086005.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.004"},{"key":"2026010906401623000_16.1.e086005.19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"The Lancet"},{"key":"2026010906401623000_16.1.e086005.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"2026010906401623000_16.1.e086005.21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(23)00052-9","article-title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-086005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:40:26Z","timestamp":1767969626000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-086005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2024-086005"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-086005","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}